Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) Gross Margin (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Gross Margin for 9 consecutive years, with 10.42% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin fell 8177.0% year-over-year to 10.42%, compared with a TTM value of 93.34% through Sep 2025, down 10.0%, and an annual FY2024 reading of 93.0%, down 700.0% over the prior year.
  • Gross Margin was 10.42% for Q3 2025 at BioRestorative Therapies, down from 97.12% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q2 2023 and bottomed at 10.42% in Q3 2025.
  • Average Gross Margin over 3 years is 85.9%, with a median of 92.72% recorded in 2024.
  • Peak annual rise in Gross Margin hit 441bps in 2025, while the deepest fall reached -8177bps in 2025.
  • Year by year, Gross Margin stood at 100.0% in 2023, then dropped by -8bps to 92.29% in 2024, then crashed by -89bps to 10.42% in 2025.
  • Business Quant data shows Gross Margin for BRTX at 10.42% in Q3 2025, 97.12% in Q2 2025, and 88.36% in Q1 2025.